Tumor necrosis factor receptor superfamily member 1A signalling complex (TNFR1-SC)

The Tumor necrosis factor receptor superfamily member 1A (TNFR1) signalling complex is a dynamic multi-protein assembly that forms upon the binding of tumor necrosis factor-alpha (TNF-alpha) to the TNFR1 receptor [1]. This complex is a critical mediator of cellular responses, existing in two primary functional forms: Complex I and Complex II [3]. Complex I is membrane-associated and recruits adaptor proteins like TRADD and RIPK1 to activate pro-inflammatory and pro-survival pathways, such as NF-kappa B and MAPK [1, 5]. In contrast, Complex II dissociates from the receptor and triggers programmed cell death through apoptosis or necroptosis, depending on the cellular context and ubiquitination status [3, 5]. Dysregulation of the TNFR1 signalling complex is a hallmark of various inflammatory and autoimmune disorders, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease [2, 3]. It also plays a significant role in the pathogenesis of neurodegenerative diseases like multiple sclerosis and the progression of certain cancers [1, 2]. Therapeutic strategies targeting this complex include monoclonal antibodies that neutralize TNF-alpha, as well as next-generation selective TNFR1 antagonists and small-molecule inhibitors of downstream components like RIPK1 [1, 3]. These treatments aim to suppress pathological inflammation and cell death while minimizing the side effects associated with global TNF blockade, such as the loss of TNFR2-mediated tissue repair [3]. Monitoring biomarkers like soluble TNFR1 and C-reactive protein is often used to assess disease activity and treatment efficacy [1, 4]. Overall, the TNFR1 signalling complex represents a high-value target for precision medicine in immunology and oncology [1].

Other names

TNF-RSCTNFR1 Complex ITNFR1 Complex IITNFR1-associated death domain complexp55 signaling complex

Selective inhibition of TNFR1 signaling through competitive ligand binding antagonism, neutralization of the TNF-alpha ligand to prevent complex assembly, and inhibition of intracellular kinase components such as RIPK1 to block downstream inflammatory and cell death pathways [1, 3, 5].